石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for the following 7 drugs in total from the National Medical Products Administration of China (the "NMPA"):

(1) Perindopril Arginine Tablets (10mg), being under type 4 chemical drug, regarded as passing the consistency evaluation and the second of such approval for the PRC entities. Perindopril Arginine Tablet is mainly used for the treatment of hypertension and congestive heart failure;

(2) Progesterone Injection (II) (1.112ml: 25mg), being under type 3 chemical drug and regarded as passing the consistency evaluation. Progesterone Injection (II) is mainly used for progesterone supplementation in assisted reproductive technology (ART);

(3) Labetalol Hydrochloride Injection (20ml: 100mg), being under type 3 chemical drug and regarded as passing the consistency evaluation. Labetalol Hydrochloride Injection is mainly used for the treatment of various types of hypertension (especially hypertensive crisis), for blood pressure control before surgery, for antihypertensive treatment of pheochromocytoma and for pregnancy-induced hypertension;

(4) Calcium Chloride Injection (10ml: 1g), being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Chloride Injection is mainly used for the treatment of acute hypocalcemia and magnesium poisoning;

(5) Multiple Electrolytes and Sodium Acetate Injection (500ml), being under type 3 chemical drug and regarded as passing the consistency evaluation. Multiple Electrolytes and Sodium Acetate Injection is mainly used for the treatment of isotonic dehydration accompanied by or expected with mild acidosis, and for replenishing the loss of extracellular fluid and blood volume;

(6) Multiple Electrolytes Injection (V) (500ml), being under type 3 chemical drug and regarded as passing the consistency evaluation. Multiple Electrolytes Injection (V) is mainly used for adults as a source of water and electrolytes or as an alkalinizing agent; and

(7) Levosalbutamol Hydrochloride Nebuliser Solution (3ml: 0.63mg), being under type 3 chemical drug and regarded as passing the consistency evaluation. Levosalbutamol Hydrochloride Nebuliser Solution is mainly used for the treatment or prevention of bronchospasm caused by reversible obstructive airway disease in adults and children over 6 years of age. As stated in the Company's announcement dated 4 September 2023, the Group's Levosalbutamol Hydrochloride bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 5 September 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.